Kraig Biocraft Laboratories Successfully Completes Lab-to-Field Transition for Three New Spider Silk Production Strains
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the successful completion of initial rearing cycles for three new recombinant spider silk production strains. The strains, recently transitioned from R&D to field production, have demonstrated excellent vitality and strong alignment with large-scale production targets.
The company is now focusing on expanding egg inventories through July and preparing for a second rearing cycle in early August. This achievement validates Kraig Labs' development pipeline and enhanced fiber engineering platform, marking a significant milestone in their strategy to deploy advanced spider silk genetics into operational production.
Kraig Biocraft Laboratories (OTCQB: KBLB), un'azienda biotecnologica specializzata nella tecnologia della seta di ragno, ha annunciato il completamento con successo dei cicli iniziali di allevamento per tre nuove linee di produzione di seta di ragno ricombinante. Le linee, recentemente passate dalla fase di ricerca e sviluppo alla produzione sul campo, hanno mostrato ottima vitalità e un forte allineamento con gli obiettivi di produzione su larga scala.
L'azienda ora si concentra su espandere le scorte di uova fino a luglio e prepararsi per un secondo ciclo di allevamento all'inizio di agosto. Questo risultato convalida il pipeline di sviluppo di Kraig Labs e la piattaforma avanzata di ingegneria delle fibre, segnando un traguardo importante nella loro strategia di implementare genetiche avanzate della seta di ragno nella produzione operativa.
Kraig Biocraft Laboratories (OTCQB: KBLB), una empresa biotecnológica especializada en tecnología de seda de araña, ha anunciado la finalización exitosa de los ciclos iniciales de cría para tres nuevas cepas de producción de seda de araña recombinante. Las cepas, recientemente trasladadas de I+D a producción en campo, han demostrado una excelente vitalidad y una fuerte alineación con los objetivos de producción a gran escala.
La compañía ahora se está enfocando en ampliar el inventario de huevos hasta julio y prepararse para un segundo ciclo de cría a principios de agosto. Este logro valida la línea de desarrollo de Kraig Labs y su plataforma mejorada de ingeniería de fibras, marcando un hito significativo en su estrategia para implementar genética avanzada de seda de araña en la producción operativa.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 거미줄 기술을 전문으로 하는 생명공학 회사로서, 세 가지 새로운 재조합 거미줄 생산 균주의 초기 사육 주기를 성공적으로 완료했다고 발표했습니다. 이 균주들은 최근 연구개발 단계에서 현장 생산 단계로 전환되었으며, 우수한 생명력과 대규모 생산 목표에 잘 부합하는 성과를 보였습니다.
회사는 현재 7월까지 알 재고를 확대하고 8월 초 두 번째 사육 주기를 준비하는 데 집중하고 있습니다. 이번 성과는 Kraig Labs의 개발 파이프라인과 향상된 섬유 공학 플랫폼을 검증하며, 첨단 거미줄 유전자를 실질적 생산에 적용하려는 전략에서 중요한 이정표가 되었습니다.
Kraig Biocraft Laboratories (OTCQB : KBLB), une entreprise de biotechnologie spécialisée dans la technologie de la soie d'araignée, a annoncé la réussite des premiers cycles d'élevage pour trois nouvelles souches de production de soie d'araignée recombinante. Ces souches, récemment passées de la R&D à la production sur le terrain, ont démontré une excellente vitalité et une forte adéquation avec les objectifs de production à grande échelle.
L'entreprise se concentre désormais sur l'expansion des stocks d'œufs jusqu'en juillet et la préparation d'un second cycle d'élevage début août. Cette réussite valide la pipeline de développement de Kraig Labs et sa plateforme améliorée d'ingénierie des fibres, marquant une étape importante dans leur stratégie visant à déployer une génétique avancée de la soie d'araignée en production opérationnelle.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein Biotechnologieunternehmen spezialisiert auf Spinnenseidentechnologie, hat den erfolgreichen Abschluss der ersten Aufzuchtzyklen für drei neue rekombinante Spinnenseiden-Produktionsstämme bekanntgegeben. Die Stämme, die kürzlich von der Forschung und Entwicklung in die Feldproduktion überführt wurden, zeigten ausgezeichnete Vitalität und eine starke Übereinstimmung mit den Zielen der großflächigen Produktion.
Das Unternehmen konzentriert sich nun darauf, den Eierbestand bis Juli zu erweitern und sich auf einen zweiten Aufzuchtzyklus Anfang August vorzubereiten. Dieser Erfolg bestätigt die Entwicklungspipeline von Kraig Labs sowie die verbesserte Faserengineering-Plattform und markiert einen bedeutenden Meilenstein in ihrer Strategie, fortschrittliche Spinnenseidengenetik in die operative Produktion zu überführen.
- Successful transition of three new spider silk strains from lab to field production
- Strong performance and vitality demonstrated in initial field rearing cycles
- Validation of development pipeline and scalability of fiber engineering platform
- Rapid deployment capability from concept to production
- Early-stage development with no immediate revenue impact mentioned
- No specific production metrics or financial data provided
Newly Deployed Strains Deliver Strong Performance in Initial Field Rearing Cycles, Paving the Way for Accelerated Deployment of Next-Generation Transgenics
ANN ARBOR, Mich., July 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces the successful completion of the first rearing cycles for its three newest recombinant spider silk production strains. These newly developed strains were transitioned from the Company's R&D program into field production earlier this quarter and have now completed their first rearing cycle, delivering strong performance across key production metrics.
This successful lab-to-field transition marks a critical milestone in the Company's strategy to rapidly deploy advanced spider silk genetics into its operational model. All three new strains demonstrated excellent vitality and a strong alignment with large-scale production targets. These initial results validate the Company's development pipeline and underscore the scalability of its enhanced fiber engineering platform.
"This achievement demonstrates not only the power of our new transgenic lines but also the speed with which Kraig Labs can move innovations from concept to production," said Jon Rice, COO of Kraig Labs. "With these new strains already in cocoon, we are now focused on rapidly expanding egg inventories through July and preparing for a second rearing cycle starting in early August."
The three strains now entering the cocoon stage represent the latest step in the Company's broader production roadmap. Kraig Labs is aggressively ramping up its egg multiplication efforts, which will supply the next generation of production cycles and integrate these powerful new lines into the Company's commercial operations. The successful launch of these strains provides strong proof of concept for future generations of even more advanced transgenic silks, currently under development.
"These early results are a powerful signal of what's ahead," Rice continued. "As we continue to build the world's first cost-effective and scalable spider silk production platform, this milestone sets the stage for deploying our most advanced technologies into the field with speed and confidence."
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What did Kraig Biocraft Laboratories (KBLB) announce about their spider silk production strains?
When will KBLB begin the second rearing cycle for their new spider silk strains?
What is the significance of KBLB's new spider silk strain development?
How will these new strains impact KBLB's commercial operations?
